eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2011
vol. 62
 
Share:
Share:
more
 
 
abstract:

Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report

Arnis Āboliņš
,
Andrejs Vanags
,
Genadijs Trofimovičs
,
Edvīns Miklaševičs
,
Jānis Gardovskis
,
Ilze Štrumfa

Pol J Pathol 2011; 1: 65–68
Online publish date: 2011/05/11
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Breast cancer is the most common cancer in women. The mortality remains significant despite advanced treatment possibilities. The management of breast cancer is guided by immunohistochemical data that are summarized into molecular subtypes, namely, luminal A, luminal B, HER2 positive and triple negative. HER2 positive and triple negative subtypes of breast cancer are considered to be biologically distinct. We present a case of clinically aggressive breast cancer in a 58-year-old female. Along the course of the disease, the molecular type switched from HER2 positive to triple negative. The patient deteriorated despite combined therapy. We recommend making a possible change of the molecular subtype and employing repeated immunohistochemical investigation in case of relapse.
keywords:

breast cancer, immunohistochemistry, molecular subtype

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.